Should low-risk DCIS lose the cancer label? An evidence review.

Saved in:
Bibliographic Details
Title: Should low-risk DCIS lose the cancer label? An evidence review.
Authors: Ma T; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia., Semsarian CR; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia., Barratt A; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia.; Wiser Healthcare, Sydney, Australia., Parker L; Sydney School of Pharmacy, Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia., Pathmanathan N; Western Sydney Local Health District, Sydney, Australia.; Westmead Breast Cancer Institute, Westmead Hospital, Sydney, Australia., Nickel B; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia., Bell KJL; School of Public Health, The University of Sydney, Sydney, NSW, 2006, Australia. katy.bell@sydney.edu.au.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Jun; Vol. 199 (3), pp. 415-433. Date of Electronic Publication: 2023 Apr 19.
Publication Type: Journal Article; Review
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1573-7217
DOI:10.1007/s10549-023-06934-y